Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vascular Biogenics stock

Own Vascular Biogenics stock in just a few minutes.

Vascular Biogenics Ltd is a biotechnology business based in the US. Vascular Biogenics shares (VBLT) are listed on the NASDAQ and all prices are listed in US Dollars. Vascular Biogenics employs 38 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vascular Biogenics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VBLT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vascular Biogenics share price

Use our graph to track the performance of VBLT stocks over time.

Vascular Biogenics shares at a glance

Information last updated 2021-03-10.
52-week range$0.90 - $3.17
50-day moving average $2.31
200-day moving average $1.65
Wall St. target price$5.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.50

Buy Vascular Biogenics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vascular Biogenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vascular Biogenics financials

Revenue TTM $843,000
Gross profit TTM $399,000
Return on assets TTM -28.55%
Return on equity TTM -57.95%
Profit margin 0%
Book value $0.78
Market capitalisation $93 million

TTM: trailing 12 months

Shorting Vascular Biogenics shares

There are currently 3.3 million Vascular Biogenics shares held short by investors – that's known as Vascular Biogenics's "short interest". This figure is 83.9% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Vascular Biogenics shares can be evaluated.

Vascular Biogenics's "short interest ratio" (SIR)

Vascular Biogenics's "short interest ratio" (SIR) is the quantity of Vascular Biogenics shares currently shorted divided by the average quantity of Vascular Biogenics shares traded daily (recently around 1.4 million). Vascular Biogenics's SIR currently stands at 2.36. In other words for every 100,000 Vascular Biogenics shares traded daily on the market, roughly 2360 shares are currently held short.

However Vascular Biogenics's short interest can also be evaluated against the total number of Vascular Biogenics shares, or, against the total number of tradable Vascular Biogenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vascular Biogenics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vascular Biogenics shares in existence, roughly 40 shares are currently held short) or 0.0474% of the tradable shares (for every 100,000 tradable Vascular Biogenics shares, roughly 47 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vascular Biogenics.

Find out more about how you can short Vascular Biogenics stock.

Vascular Biogenics share dividends

We're not expecting Vascular Biogenics to pay a dividend over the next 12 months.

Vascular Biogenics share price volatility

Over the last 12 months, Vascular Biogenics's shares have ranged in value from as little as $0.9 up to $3.17. A popular way to gauge a stock's volatility is its "beta".

VBLT.US volatility(beta: 0.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vascular Biogenics's is 0.8808. This would suggest that Vascular Biogenics's shares are less volatile than average (for this exchange).

Vascular Biogenics overview

Vascular Biogenics Ltd. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site